New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
AbbVie proposes $46bn bid for Shire; fifth offer of $53.3bn accepted; deal terminated in response to new US tax code
Jun 2014
Executive Summary
On the heels of Pfizer Inc.’s failed takeover attempt of AstraZeneca PLC, AbbVie Inc. proposed to pay $46bn (£27bn) for Shire PLC, whose stockholders would receive $34.78 in cash and 0.7988 ordinary AbbVie shares for each share held (worth $78.07, a 58% discount). (AbbVie’s initial offer on May 5th valued each Shire share at $65.72 and its second bid on May 14th was $67.35.)
Deal Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie proposes $46bn bid for Shire; fifth offer of $53.3bn accepted; deal terminated in response to new US tax code
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice